European Monitoring Centre
for Drugs and Drug Addiction

EMCDDA/18/17

FINAL MINUTES OF THE FIFTY–FIFTH MEETING OF THE MANAGEMENT BOARD (29–30 JUNE 2017)

29 JUNE

Introduction by the Chair

The **Chair, Ms Laura d'Arrigo,** expressed, on behalf of the Management Board, condolences to Portugal for the recent forest fires and to the United Kingdom for the latest terrorist attack and fire of the Grenfell Tower.

The Chair informed the Management Board members about the new nominations since the last meeting: Ms Sofie Dencker was nominated as substitute member for Denmark, Ms Maria Afxentiou as substitute member for Cyprus and Ms Lauren Comber as substitute member for the United Kingdom. Mr İbrahim H. Seydioğullari was designated as member for Turkey.

The Chair welcomed the participants and in particular the new members on the Management Board. Mr Nicolas Prisse represents France as substitute member. Ms Maria Contento was nominated as member and Ms Elisabetta Simeoni as substitute member for Italy. Ms Johanna Schopper was designated as substitute member for Austria, Mr Henrik Melin as member for Sweden and Mr Murat Sarikamșili as substitute member for Turkey.

The Chair also welcomed some observers to the meeting. In the absence of the substitute member, Ms Katerina Horáčková from the Secretariat of the Council of the Government for Drug Policy joined the member from the Czech Republic during this meeting. Ms Carmela D'Urso, from the Department for Anti-drug Policies, accompanied the Italian delegation. Ms Sara Wall, from the Public Health Agency of Sweden, joined Mr Henrik Melin, in particular for the discussion on new psychoactive substances (NPS).

The Chair greeted Mr Olivier Onidi, Deputy General Director for Security of the Directorate-General Migration and Home Affairs (DG HOME) as new member for the European Commission. Mr Wojciech Kałamarz, Head of the 'Health Determinants' Unit (DG SANTE) has been nominated as new substitute member. Ms Ute Stiegel, acting Head of the 'Organised Crime and Drugs Policy' Unit (DG HOME), replaces Ms Floriana Sipala until September 2017. Ms Paola Mazzarini, responsible for the coordination with the EMCDDA at DG HOME, accompanied the delegation as observer.

Ms d'Arrigo welcomed Ms Anne Line Bretteville-Jensen, who was elected in May as new Chair of the EMCDDA Scientific Committee for a three-year mandate.

Bulgaria, Ireland and UNODC were not represented at the meeting. Bulgaria gave its proxy vote to Romania.

The Chair welcomed the interpreters, providing simultaneous interpretation from and into French, English, and German. Members could in addition speak Estonian, Polish and Swedish. The Budget and Executive Committee met on 29 June 2017 in order to prepare the Management Board meeting.

The Chair reminded that all Management Board members, substitutes and observers were invited by the French Ambassador for a reception at the end of the meeting.

Finally, Ms d'Arrigo announced some security measures in case of a fire alarm and evacuation of the building.

1. Adoption of the agenda

EMCDDA/01/17 rev 1
EMCDDA/02/17

The **Director** suggested adding a point for information under 'Any other business' on the revision of the Memorandum of Understanding between the EMCDDA and WHO.

Decision: The Management Board adopted the revised agenda of the meeting.

2. Activity reports:

2.1. Report on the activities of the Chair

EMCDDA/03/17

The **Chair** briefly reported on her participation in the EMCDDA Scientific Committee meeting on 22 May, and in the launch of the *European Drug Report* 2017 in the presence of Commissioner Avramoupoulos and the EMCDDA Director at the European Commission on 6 June 2017.

2.2. Report from the Budget Committee

EMCDDA/04/17

The **Chair of the Budget Committee** informed the Board members about the discussions held at the Budget Committee meetings of 11 May and 29 June.

2.3. Report on the external activities of the Director

EMCDDA/05/17

The **Director** briefly reported about his external activities. He highlighted the EMCDDA's Chairmanship of the network of Justice and Home Affairs (JHA) Agencies in 2017, and in particular the expert meeting on 'The expanding influence of the internet, the exploitation of cyberspace and the transformational nature of new technologies', which was organised by the EMCDDA in April. The conclusions of the Chairmanship will be communicated to the Directors of JHA Agencies at a meeting on 28 November 2017 at the EMCDDA with the participation of Commissioner Avramoupoulos, to the Management Board in December, as well as to the Civil Liberties, Justice and Home Affairs Committee (LIBE) of the European Parliament and to the Standing Committee on Operational Cooperation on Internal Security (COSI) of the Council.

The Director participated in the HIV Conference on 'Fast-track the end of AIDS in the EU practical evidence-based interventions', which was organised under the Maltese Presidency, in collaboration with the European Centre for Disease Prevention and Control (ECDC), in January in Malta. On this occasion he launched a common initiative for JHA Agencies on 'Migration and Health'.

Finally, the Director informed about the informal visit of the European Commissioner for Energy and Innovation, Mr Carlos Moedas, to the EMCDDA on 8 May 2017.

3. Presentations by EU Presidencies

3.1. Presentation on the conclusions of the Maltese Presidency

Mr Richard Muscat summarised first conclusions of the **MT** Presidency.

The main priorities of the MT Presidency in terms of drugs policy were the new legal framework on NPS, for which a political agreement was reached recently, the preparation of resolutions for the CND and the Post-UNGASS 2016 process. The Horizontal Working Party on Drugs was also involved in the mid-term evaluation of the EU Drugs Strategy 2013–20, the final evaluation of the EU Action Plan on Drugs 2013–16 and the negotiations of the next EU Action Plan covering 2017–2020 which was adopted on 20 June. Expert Dialogues with third countries included the 19th EU and CELAC High-level meeting in Argentina, which resulted in the Buenos Aires declaration, and the work on misuse of prescribed medicines was continued.

The national drug coordinators meeting took place on 24 April 2017 in Malta around the theme 'Treatment not Imprisonment'.

On behalf of the Management Board, the **Chair** congratulated the MT Presidency for its important achievements, in particular concerning the new legislation on NPS.

3.2. Presentation of the programme for the Estonian Presidency

Mr Ain Peil, future Chair of the Horizontal Working Party on Drugs (HDG), from the Ministry of Interior, presented the priorities of the **EE** Presidency.

In terms of drugs policy, the main priorities of the EE Presidency are alternatives to coercive sanctions and the preparation for the 2019 review of the UN Political Declaration. The Horizontal Working Party on Drugs will prepare common positions for the Post-UNGASS 2016 process and international scheduling of NPS. Expert Dialogues with third countries will include HDG meetings with the CELAC technical committee and with the Civil Society Forum, as well as EU dialogues with the US, Central Asia, and with Eastern partnership countries.

The national drug coordinators meeting will take place on 13–14 September 2017 in Tallinn and will focus on challenges regarding the fentanyl epidemic.

On behalf of the Management Board, the **Chair** ensured EE of the support for its Presidency, which marks the beginning of the next EU Action Plan, and welcomed the theme of the national drug coordinators meeting.

4. Points for decision/adoption by the Management Board:

4.1. EMCDDA 2016 final accounts: opinion of the Management Board — EMCDDA/06/17

The **Director** presented for the first time the highlights of the budgetary and financial performance, as well as the main achievements of the EMCDDA in 2016 based on the General Report of Activities for last year.

Mr Claude Gillard, **Chair of the Budget Committee,** stressed the excellent budget performance, with the highest execution rate ever for commitment appropriations of 99.95% and an execution rate for payment appropriations of 95.64%, which enabled the EMCDDA to avoid budget-related penalisation. He reported that the preliminary observations of the European Court of Auditors state that the transactions underlying the annual accounts for 2016 are legal and regular, and include only one technical comment. The Budget Committee analysed the EMCDDA final accounts for 2016, and recommended to the Management Board to adopt the opinion on these accounts.

Decision: The Management Board gave a favourable opinion on the EMCDDA's final annual accounts for 2016.

The **Chair** congratulated on behalf of the Management Board the Director and his staff, in particular the Head of Administration, Mr Dante Storti, the accountant, Mr Pascal Jonjic, the deputy accountant, Ms Ljiljana Veljkovic-Dieudonné, and the financial team, for the collective effort and excellent budgetary execution.

4.2. Amending budget no 1 to the EMCDDA budget for 2017 — EMCDDA/07/17

The **Chair of the Budget Committee** informed that EUR 340 000 have to be entered into the EMCDDA 2017 budget for the execution of a new project for technical assistance to the beneficiary countries of the EU Instrument for Pre-accession Assistance (IPA 6). The contract will be signed in July or August, and the project will have a duration of 24 months. In addition, an amount of about EUR 1 500 have to be entered into the budget as supplementary revenue from bank interests generated by the funds paid to the EMCDDA. The Budget Committee recommended to the Management Board to adopt the amending budget no 1 to the 2017 budget.

The Budget Committee will examine the key elements of an amending budget no 2 to the 2017 budget at its meeting in October. In order to enter into the budget supplementary revenue for the EU4Monitoring Drugs project, the necessary adjustments of salary costs, revenue from bank interests and adjustments to the implementation of the work programme, an amendment to the budget may be needed. This second amendment to the 2017 budget will have to be adopted by the Management Board by written procedure.

Decision: The Management Board adopted the amending budget no 1 to the EMCDDA budget for 2017.

4.3. Working arrangements between the EMCDDA and the Federal Office of Public Health of Switzerland **EMCDDA/08/17**

At its meeting in December 2015, the Management Board decided in favour of a more formal framework of cooperation between the EMCDDA and the Federal Office of Public Health of Switzerland, further to a request of the latter dated 7 August 2015. The European Commission issued a formal opinion on the draft working arrangements on 22 May 2017.

The **Director** informed that the signature of the working arrangements would probably be organised by October 2017. A multi-annual work programme will be annexed to the working arrangements and will be shared with the Management Board members.

Decision: The Management Board took note of and agreed with the Working Arrangements between the EMCDDA and the Federal Office of Public Health of Switzerland, and mandated the Director to sign the Working Arrangements on a date and place to be jointly decided between the Director of the Federal Office of Public Health of Switzerland and the EMCDDA Director.

4.4. Nomination of an alternate observer for the Pompidou Group of the Council of Europe **EMCDDA/09/17**

On 7 February 2017, the Pompidou Group of the Council of Europe informed the Chair of the EMCDDA Management Board of its wish to nominate Ms Elena Hedoux as alternate observer of the Pompidou Group to the EMCDDA Management Board.

The Chair of the EMCDDA Management Board proposed that Ms Elena Hedoux may attend the meetings of the EMCDDA Management Board as alternate observer of the Pompidou Group, in case of non-attendance of the designated observer of the Pompidou Group.

Decision: The Management Board agreed that Ms Elena Hedoux may attend the meetings of the EMCDDA Management Board as alternate observer of the Pompidou Group, in case of non-attendance of the designated observer of the Pompidou Group.

4.5. Planning of meetings for 2018 **EMCDDA/10/17**

Decision: The Management Board endorsed the calendar of Management Board, Executive Committee and Budget Committee meetings for 2018.

5. Points for discussion:

5.1. New psychoactive substances: challenges and perspectives

Ms Ute Stiegel, representative of the European Commission, presented the new EU legal framework on NPS, on which political agreement was achieved on 29 May 2017. The new legislation consists of two elements: a Regulation amending the founding Regulation of the EMCDDA and the Directive amending Council Framework Decision 2004/757/JHA laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking. Its objective is to reduce the availability of NPS that pose risk through swifter, more effective action at Union level as compared to the system currently applicable (based on Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances). This new legislation will be adopted formally in November/December 2017 and will be applicable in practice by the end of 2018.

Dr Roumen Sedefov, Head of the 'Supply reduction and new drugs' Unit, shared the EMCDDA analysis on the challenges and perspectives for monitoring and risk assessments of NPS. Dr Sedefov reminded that the Joint action on new synthetic drugs was adopted on 16 June 1997, twenty years ago. The Early Warning System and Risk Assessments are unique at world level, and allow the EU to rapidly identify and respond to public health and security threats through intensive and multi-disciplinary cooperation between the Member States, the European Commission and Agencies. In addition, the EMCDDA activity feeds directly into the EU decision making process that may result in legislative acts to control NPS as drugs.

Several Member States presented innovative models at national level.

Mr Jörg Pietsch described the recent new legislative approach in **DE**. In order to improve measures against NPS, the Federal Ministry of Health has initiated a new, separate law with a new approach: the Act on New Psychoactive Substances (German abbreviation: NpSG). This new law came into force in November 2016. From now on, the considerable health risks resulting from NPS in particular for youths and young adults are addressed more effectively by controlling groups of substances (generic approach). This will limit the possibilities for circumventing the control measures by minor chemical alterations and, therefore, will limit the number of dangerous substances on the market.

Ms Ute Stiegel wondered about the possible effects of this recent law on the NPS market. **DE** replied that a quantitative and qualitative evaluation of the impact of the new law will be carried out from June 2017 to May 2019. This evaluation will take into account the impact of the new law on consumers, the healthcare system, law enforcement entities (police, customer services, justice), the market and forensic and emergency services. DE would be interested in any information about the prevalence, shares of NPS on the market (online shops, sale inside and outside the EU, street sale, direct sale), etc.

Mr Tim Pfeiffer-Gerschel, the Spokesperson of the Reitox national focal points, informed that the German focal point has been involved in the drafting of the new law, and that a kick-off meeting for its comprehensive evaluation is planned to take place soon.

Ms Bogusława Bukowska described the amendments in the legislation on NPS in **PL** between 2009 and 2015, and the preventive measures taken since the beginning of the current NPS phenomenon in the country. PL used strategies which are useful in drug prevention, trying to reach all important actors. The preventive efforts have been positively assessed as having been undertaken very early, involving all important stakeholders, reaching the relevant target groups, and providing appropriate tools.

Ms Sara Wall, from the **Public Health Agency of SE**, presented the Swedish monitoring system for NPS, as well as the challenges and strengths in terms of detecting and responding to harms.

30 JUNE

Ms Rosanna O'Connor provided an update on the **UK** legislation and treatment approaches to NPS use. The Psychoactive Substances Act 2016 (PSA) came into force on 26 May 2016. The presentation included information on the Neptune project, an evidence-based clinical guidance developed to raise standards in clinical management of harms from 'club drugs' and NPS. Public Health England is also currently piloting a system to collect information on adverse reactions to NPS. A recent phenomenon is that problematic NPS use is affecting vulnerable and marginalised populations; in particular high prevalence of synthetic cannabinoid use can be noted among the prison population. Echoing the EMCDDA presentation, Ms O'Connor suggested that the appearance and use of fentanils and related problems could be a topic for a future thematic debate at the Management Board.

The **Chair of the Scientific Committee** inquired if there is data on the prevalence rates on NPS use in prisons. **UK** replied that the National drug treatment monitoring system has a valuable data set and that a report on prisons' data for 2016 will be published in the autumn.

The **Director** expressed his thanks for all interesting presentations. He assured that the EMCDDA wishes to continue the cooperation with the UK in the future, and mentioned that it came to his attention that for budgetary reasons the UK crime survey will not include questions on drugs any more. The **UK** representative will check this issue with the Home Office.

Dr Roumen Sedefov stressed once again the great complexity of the drug markets, and the preventability of fentanils overdoses by, amongst others, making naloxone programmes available to relevant user groups. It is also important to streamline and refine the risk communication for users and the general population in this area.

EE stressed that NPS are not a homogeneous group of substances, and that it is necessary to take into account various user groups in the approaches at all levels – legislation, prevention, treatment, etc.

Mr Wojciech Kalamarz, representative of the European Commission, informed that a three-year project called EPPIC started in March 2017 on the exchange in preventing practices on poly-drug use among the youth in criminal justice systems, in 6 partner countries (AT, DK, DE, IT, PL, UK). The Project Advisory Board, which includes also EMCDDA experts, representatives from DG HOME and DG SANTE, will meet in January 2018 in Warsaw.

FI pointed out that it is important to include the role of customs and research about the Darknet markets in the discussion.

After the change of legislation on NPS in PL, a similar legislation was also introduced in **CZ**. The NPS phenomenon has slowed down, but **CZ** warned about attributing overall success to the legislation, as NPS will continue to appear on the market.

NL informed about national research on Darknet, carried out by the Ministry of Justice on the role of online markets as part of the overall drug market including NPS, as well as the studies from NPS consumers' points of view. NL wondered if DE planned to ban also more groups of substances such as cathinones.

DE explained that the two groups of substances included in the German law cover about approximately 70% of the NPS currently on the market, and that groups of experts are discussing the possible extension to other groups.

The **Chair** added that in FR synthetic cathinones and synthetic cannabinoids were put under control through 'generic/family group approach' legislative acts. In order to have certainty of the chemical identity of the NPS included in the law, the act mentions the NPS chemical compositions.

Ms Ute Stiegel recalled that the new EU Action Plan on Drugs represented the point of reference for activities in the area of NPS, for example, through actions on prevention, naloxone programmes and on online trading and new technologies.

Mr Murat Sarikamşili briefly presented the generic classification law for NPS entered into force in **TR** in 2015 because of the synthetic cannabinoids problem, which allowed bringing 276 NPS under control.

Mr Tomas Zabransky, representative of the European Parliament, welcomed the tradition of evaluating drug policies by scientific means. He proposed to exchange information on the Darknet gathered by a scrap tool in FR, and another by CZ and NL, and to explore the legislation on NPS in New Zealand.

Dr Roumen Sedefov noted that the role of the EMCDDA and the NFPs is to streamline the terminology on NPS. Controlling NPS by listing them individually in the drug laws has proven successful as it limits the availability of the most harmful NPS and lowers the case of the acute toxicity, including deaths linked to them. It is clear however that such an approach does not prevent the appearance of new substances which rapidly replace those under control. Blanket bans and generic legislation have an observable effect on the overall availability and accessibility of NPS even before the result of a scientific evaluation. The EMCDDA and Europol will publish before the end of the year a report on the Darknet drug markets.

HU launched a new legislation on NPS in 2012, which includes a mix of generic classification and list of individual substances. The amount of seized NPS decreased slowly as of 2014.

FR expressed interest in sharing the methodology used by the Ministry of Interior and the Customs for analysing the Darknet.

Mr Olivier Onidi, representative of the European Commission, welcomed the thematic debates held at EMCDDA Management Board meetings. He thanked the MT Presidency and the EP for the political agreement reached on the new EU legislation on NPS, and reminded about the collective responsibility to implement it in the best possible way. The European Commission will provide all its support to the EMCDDA which is at the heart of the new mechanism. Mr Onidi underlined the importance of the quality and periodicity of the data, which should be continued to be transmitted by the Member States to the Agency, and of data from other sources such as Europol and Frontex. The exchange of experiences and practices can also be very useful when anticipating Risk Assessments of NPS.

Finally, Mr Onidi reminded that the next external evaluation of the EMCDDA will be launched in 2018. The exercise should be discussed at an early stage at a Management Board meeting, to maximize the input.

Stressing the complementarity between EU and national legislations and approaches on NPS, the **Chair** concluded that the discussion had allowed a very fruitful exchange, emphasised the operational role of the EMCDDA in this field and the importance of a continuous collaboration of Member States and NFPs with the agency.

6. Points for information:

6.1. State of play of the implementation of the EMCDDA Strategy 2025 — EMCDDA/11/17

The **Director** updated the Management Board on the implementation of the EMCDDA Strategy 2025, which was adopted by the Board at its meeting of 15–16 December 2016, in particular about the changes in the organisational design and the staff management.

The **Chair** thanked the Director on behalf of the Management Board for his transparency.

6.2. Inter-LINK project — EMCDDA/12/17

The **Director** stressed that the project, which is managed by DG NEAR of the European Commission and is now entitled 'EU4 Monitoring Drugs', is innovative as it will cover Neighbourhood East and South countries and their neighbouring countries, and will allow to acquire further knowledge on trafficking trends and assessment of risks to better evaluate the impact on the EU markets. The project will provide a dynamic platform for the identification, analysis and reporting of security and health threats posed by developments in the contemporary drug markets and their links with other related security and health issues, and will be implemented in close cooperation with Europol and Frontex.

The **Chair of the Budget Committee** noted that if the contract is signed before the end of 2017, the revenue will have to be entered through an amendment no 2 into the EMCDDA budget for 2017. The total earmarked budget is EUR 3 million (EUR 2 million from ENP South and EUR 1 million from East regional allocations) for a total duration of 36 months (extendible if there are delays).

6.3. Information on procurements for non-administrative activities of an estimated value greater than EUR 60 000 to implement the 2017 work programme — EMCDDA/13/17

According to the Financial Regulation applicable to the EMCDDA, the **Director** informed the Management Board members about procurements for non-administrative activities of an estimated value equal to or greater than EUR 60 000.

6.4. Update on the IAS Final Report on the Limited Review on Business Continuity at the EMCDDA and the EMCDDA Action Plan — EMCDDA/14/17

The **Chair** welcomed the considerable improvements in the relations between the EMCDDA and the Internal Action Service of the European Commission.

6.5. EMCDDA's budget for 2018: oral report on the state of play of the budget procedure by the European Commission

Mr Olivier Onidi, representative of the European Commission, informed that the Commission adopted the draft EU budget for 2018 on 30 May, with a total level of the EU contribution to EMCDDA for 2018 amounting to EUR 15 445 600. This proposal includes the request of the EMCDDA in its preliminary draft budget for 2018 for additional amount of EUR 310 000 for the coordination and the development of the activities of the European School Survey Project on Alcohol and Other Drugs (ESPAD) in 2018.

The total number of the EMCDDA establishment plan posts is 76, as foreseen in the 2013 Commission Communication on the 'Programming of human and financial resources for decentralised agencies 2014–2020'. This means one less than the number requested by the Centre, which based itself on the levels of 2017. As regards contract agents, the Commission also supported the Centre's request for one additional contract agent to carry out the activities related to the ESPAD project.

The Commission has submitted the draft 2018 EU budget to the European Parliament and the Council. The Council will adopt its opinion on the draft 2018 EU budget over the summer and the European Parliament in autumn. The conciliation committee will last from 31 October to 20 November, and the European Parliament should adopt the EU budget for 2018 in the plenary session of end of November or in December.

The **Chair of the Budget Committee** reminded that the draft budget for 2018 has to be adopted by the Management Board in December.

The **Chair** thanked the Commission for its constant support to the EMCDDA in the budgetary procedure and for having included in its preliminary draft budget the ESPAD project.

6.6. Launch of the 2017 *European Drug Report* and uptake (Brussels, 6 June 2017) EMCDDA/11/17

The **Chair** congratulated the EMCDDA Director and his staff on the 2017 European Drug Report. Ms d'Arrigo thanked the Communication team for the simplified messages of the report and the organisation of the launch, for which the presence of Commissioner Avramoupoulos guaranteed greater visibility.

The **Director** provided the Board members with the most recent figures concerning the uptake of the report. During Week 2 following the launch, a total up to 3 392 news items were tracked, up by 24% on last year's 2 740 items at this stage. The EMCDDA has not invited paid journalists to the launch this year, as the number of drug specialised journalists has decreased, but the preliminary results of the media coverage show no negative changes. The EMCDDA will develop a comprehensive analysis on the meaning of communication nowadays, to ensure that it reaches its priority customers. Further reflection will be developed about how to better target the international press for the launch of the European Drug Responses Report in autumn.

NO thanked the EMCDDA for the participation of Mr Brendan Hughes at its national launch of the European Drug Report on 6 June 2017. An internal seminar on cannabis legislation in Europe was organised for authority stakeholders from all sectors related to drug policy, during which the European Drug Report and the Norwegian national report were presented.

DK congratulated the EMCDDA on the excellent European Drug Report and Country Drug Reports, and thanked the national focal points for their indispensable contribution to the report. A close and trustful cooperation between the EMCDDA and the national focal points is crucial – not least with regard to the more sensitive parts of the reports such as the parts on mortality and drug-related deaths.

6.7. Second European Conference on addictive behaviours and dependencies (Lisbon, 24–26 October 2017): presentation by the Portuguese delegation EMCDDA/16/17

PT presented the main features and key dates for the second European Addiction Conference to the Management Board members. The Conference will be organised on 24–26 October 2017 by the Portuguese SICAD (Serviço de Intervenção em Comportamentos Aditivos e Dependências – General Directorate for Intervention on Addictive Behaviours and Dependencies), the journal Addiction (of the Society for the Study of Addiction), the EMCDDA and ISAJE (International Society of Addiction Journal Editors). Mr Manuel Cardoso thanked the EMCDDA for its excellent collaboration and valuable support.

SICAD received more than 500 submissions for paper presentations, posters as well as structures sessions. Also as part of the programme of Lisbon Addictions 2017, the TWIST project (Training With Stakeholders – applying EU drug and addiction research), a project funded by the European Commission under the Justice Programme, will provide a two-day training programme, aimed at early-stage addiction researchers and professionals.

NL added that the project leaders of the European research project ERA-NET coordinated by the NL (BE, FR, IT, NL, PT, UK) will present their results at the Lisbon Addictions Conference. The website of the project will be maintained to disseminate its results. A follow-up of the project would be welcome.

The **Chair** thanked Portugal for its commitment and the EMCDDA for its contribution to this important event for researchers and public authorities.

6.8. Assessment of the implementation of the EMCDDA Policy for the prevention and management of conflicts of interest for Management Board members, substitutes and observers EMCDDA/17/17

The **Chair** announced that all declarations of conflicts of interest have been submitted by the members, substitutes and observers of the Management Board, with some exceptions for recent nominations. The Chair added that the Director decided to fill in a declaration of interest even if he is not formally obliged to do so.

Decision: The Management Board confirmed the outcome of the screening conducted by the EMCDDA Director that has revealed that in specific cases there could be a risk of conflict of interest which will be addressed through the existing mitigating measures.

8. Any other business

– Revision of the Memorandum of Understanding with WHO

The **Director** informed the Board members about the necessity to review the terms of cooperation with WHO. The EMCDDA concluded a Memorandum of Understanding (MoU) with WHO Europe in 1995, which no longer responds to the reality that the Centre is facing, particularly in terms of NPS. The EMCDDA will consult with WHO and WHO Europe about an update or replacement of the current MoU, and hopefully inform the Management Board in December on the next steps. In case of a new MoU the European Commission will be consulted.

– TDI data collection in the Netherlands

NL drew the attention of the Management Board to a problem in the delivery of national data for the treatment demand indicator (TDI) for 2016 to the EMCDDA, as they are not considered complying with the rules of data protection. The National Alcohol and Drugs Information System collects TDI data in an individual anonymous form. According to the Dutch Privacy Authority the collection of individual data, although pseudonomized, should have a legal basis, which the system does not have currently.

The **Director** suggested the EMCDDA could organise a technical meeting and provide support to the NL in September.

Ms Ute Stiegel, representative of the European Commission, also offered support from the Commission services if needed.

The **Chair** thanked the Director and his staff for the preparation of the meeting, and the Board members for their contributions. The Chair also expressed her special thanks to the interpreters for their work.

The next meeting will take place on 14–15 December 2017.

Laura d'Arrigo
Chair of the Management Board

Annexes:	I	List of participants
	II	List of decisions and conclusions
	III	List of action points

Copy: Members, substitutes and observers of the Management Board

ANNEX I

55th meeting of the EMCDDA Management Board

Lisbon, 29–30 June 2017

LIST OF PARTICIPANTS

Belgium	Mr Claude GILLARD
Czech Republic	Mr Jindřich VOBOŘIL
	Ms Katerina HORÁČKOVÁ
Denmark	Mr Lars PETERSEN
Germany	Mr Jörg PIETSCH
Estonia	Mr Ain PEIL
Greece	Mr Gerasimos PAPANASTASATOS
Spain	Mr Francisco BABÍN VICH
France	Ms Laura d'ARRIGO
	Mr Nicolas PRISSE
Croatia	Mr Željko PETKOVIĆ
	Ms Sanja MIKULIĆ
Italy	Ms Maria CONTENTO
	Ms Elisabetta SIMEONI
	Ms Carmela D'URSO
Cyprus	Mr Stelios SERGIDES
Latvia	Mr Dzintars MOZGIS
Lithuania	Ms Inga JUOZAPAVIČIENĖ
Luxembourg	Mr Xavier POOS
Hungary	Ms Ibolya CSÁKÓ
Malta	Mr Richard MUSCAT
The Netherlands	Ms Wil DE ZWART
Austria	Mr Franz PIETSCH

	Ms Johanna SCHOPPER
Poland	Ms Bogusława BUKOWSKA
Portugal	Mr João GOULÃO
	Mr Manuel CARDOSO
Romania	Mr Sorin OPREA
Slovenia	Mr Joze HREN
Slovakia	Mr Boris BÁNOVSKÝ
	Ms Eva DEBNÁROVÁ
Finland	Ms Elina KOTOVIRTA
Sweden	Mr Henrik MELIN
	Ms Sara WALL
United Kingdom	Ms Rosanna O'CONNOR
Norway	Ms Lilly Sofie OTTESEN
Turkey	Mr Murat SARIKAMIŞLI
EUROPEAN COMMISSION	Mr Olivier ONIDI (DG HOME)
	Ms Ute STIEGEL (DG HOME)
	Mr Wojciech KAŁAMARZ (DG SANTE)
	Ms Paola MAZZARINI (DG HOME)
EUROPEAN PARLIAMENT	Mr Wolfgang GÖTZ
	Mr Tomas ZABRANSKY
WHO	Mr Lars MØLLER
POMPIDOU GROUP	Mr Thomas KATTAU
SCIENTIFIC COMMITTEE	Ms Anne Line BRETTEVILLE-JENSEN
REITOX	Mr Tim PFEIFFER-GERSCHEL
EMCDDA	Mr Alexis GOOSDEEL
	Mr Fabian PEREYRA
	Ms Monika BLUM

ANNEX II

LIST OF DECISIONS AND CONCLUSIONS

1. Adoption of the agenda **EMCDDA/01/17 rev 1**

The Management Board adopted the revised agenda of the meeting.

4. Points for decision/adoption by the Management Board:

4.1. EMCDDA final accounts for 2017 **EMCDDA/06/17**

The Management Board gave a favourable opinion on the EMCDDA's final annual accounts for 2015.

4.2. Amending budget no 1 to the EMCDDA budget for 2017 **EMCDDA/07/17**

The Management Board adopted the amending budget no 1 to the EMCDDA budget for 2017.

4.3. Working arrangements between the EMCDDA and the Federal Office of Public Health of Switzerland **EMCDDA/08/17**

The Management Board took note of and agreed with the Working Arrangements between the EMCDDA and the Federal Office of Public Health of Switzerland, and mandated the Director to sign the Working Arrangements on a date and place to be jointly decided between the Director of the Federal Office of Public Health of Switzerland and the EMCDDA Director.

4.4. Nomination of an alternate observer for the Pompidou Group of the Council of Europe **EMCDDA/09/17**

The Management Board agreed that Ms Elena Hedoux may attend the meetings of the EMCDDA Management Board as alternate observer of the Pompidou Group, in case of non-attendance of the designated observer of the Pompidou Group.

4.5. Planning of meetings in 2018 **EMCDDA/10/17**

The Management Board endorsed the calendar of Management Board, Executive Committee and Budget Committee meetings for 2018.

ANNEX III

LIST OF ACTION POINTS

Agenda point	Action to take	Responsable	Date
4.1.	Forward the final accounts, together with the opinion of the Management Board, to the Accounting Officer of the European Commission and to the European Court of Auditors, as well as to the European Parliament and to the Council	EMCDDA	June 2017
4.3.	Signature of working arrangements between the EMCDDA and the Federal Office of Public Health of Switzerland	EMCDDA Director	Autumn 2017
5.1.	Upload all presentations on the Management Board consultation site	EMCDDA	June 2017
8.	Inform the Management Board about revision of Memorandum of Understanding with WHO	EMCDDA	2017–2018
8.	Provide support to the NL concerning the TDI data delivery problem	EMCDDA	Autumn 2017